Tecentriq Archives - Page 3 of 4 -

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery. Roche had

Roche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancer

https://pharmaphorum.com/news/roches-tecentriq-cocktail-fails-in-newly-diagnosed-ovarian-cancer/

News/ News/ Oncology

Roche’s Tecentriq/Avastin combo gets liver cancer nod

George Underwood Avastin, Liver cancer, Roche, Tecentriq 0 Comment

The FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) –

Roche’s Tecentriq/Avastin combo gets liver cancer nod

https://pharmaphorum.com/news/roches-tecentriq-avastin-combo-gets-liver-cancer-nod/

Market Access/ News/ News/ News/ Oncology/ Top stories

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

Richard Staines cancer, ES-SCLC, market access, NICE, Roche, small cell lung cancer, Tecentriq 0 Comment

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/

News/ News/ Oncology/ Top stories

Roche’s Tecentriq gains new first-line lung cancer use

Richard Staines Bristol-Myers Squibb, cancer, lung cancer, Merck & Co, Roche, Tecentriq 0 Comment

Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients. Tecentriq (atezolizumab)

Roche’s Tecentriq gains new first-line lung cancer use

https://pharmaphorum.com/news/roches-tecentriq-gains-new-first-line-lung-cancer-use/

News/ News/ Oncology

Roche’s TIGIT drug shows promise in untreated lung cancer

Richard Staines cancer, immunotherapy, lung cancer, Roche, Tecentriq 0 Comment

Roche has announced positive first phase 2 results from its new kind of cancer immunotherapy, showing that adding tiragolumab to its already approved Tecentriq creates a

Roche’s TIGIT drug shows promise in untreated lung cancer

https://pharmaphorum.com/news/roches-tigit-drug-shows-promise-in-untreated-lung-cancer/

News/ News/ Oncology

Merck & Co squares up to Roche with Keytruda data in triple-negative breast cancer

Phil Taylor immuno-oncology, Keytruda, Merck & Co, Oncology, Roche, Tecentriq, triple negative breast cancer 0 Comment

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe

Merck & Co squares up to Roche with Keytruda data in triple-negative breast cancer

https://pharmaphorum.com/news/mercks-squares-up-to-roche-with-keytruda-data-in-triple-negative-breast-cancer/

News/ News/ Oncology/ Top stories

FDA to quickly review Roche’s chemo-free lung cancer regimen

Richard Staines cancer, immunotherapy, Keytruda, lung cancer, Roche, Tecentriq 0 Comment

Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the

FDA to quickly review Roche’s chemo-free lung cancer regimen

https://pharmaphorum.com/news/roche-closing-in-on-chemo-free-first-line-nsclc-regimen/

Market Access/ News/ News/ News/ Oncology

Roche files Tecentriq, Avastin combo as a liver cancer therapy

Phil Taylor bladder cancer, immuno-oncology, Liver cancer, Oncology, Roche, Tecentriq 0 Comment

Roche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular

Roche files Tecentriq, Avastin combo as a liver cancer therapy

https://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/

News/ News/ Oncology

Roche steps up Merck challenge with first-line NSCLC approval in US

Phil Taylor first-line lung cancer, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq 0 Comment

Roche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC),

Roche steps up Merck challenge with first-line NSCLC approval in US

https://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/

Trending

Tecentriq

Login